psoriasis90 {MBNMAdose}

Studies of biologics for treatment of moderate-to-severe psoriasis (>=90% improvement)

Description

A dataset from a systematic review of Randomised-Controlled Trials (RCTs) comparing biologics at different doses and placebo (Warren et al. 2019). The outcome is the number of patients experiencing >=90% improvement on the Psoriasis Area and Severity Index (PASI) measured at 12 weeks follow-up. The dataset includes 24 Randomised-Controlled Trials (RCTs), comparing 9 different biologics at different doses with placebo.

Usage

psoriasis90

Format

A data frame in long format (one row per arm and study), with 81 rows and 9 variables:

• studyID Study identifiers

• agent Character data indicating the agent to which participants were randomised

• dose_mg Numeric data indicating the dose to which participants were randomised in mg

• freq Character data indicating the frequency of the dose to which participants were randomised

• dose Numeric data indicating the dose in mg/week to which the participants were randomised

• n Numeric data indicating the number of participants randomised

• r Numeric data indicating the number of participants who achieved >=90% improvement in PASI score after 12 weeks

References

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A (2019). “Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.” J Am Acad Dermatol, 82(5), 1138-1149.